Acadia Pharmaceuticals’ CEO on Rebranding and Using AI
Acadia Pharmaceuticals CEO Catherine Owen Adams discusses the company's recent rebrand and expansion into rare disease marketing, as well as its use of AI.
Neurological biotech Acadia Pharmaceuticals has rolled out a rebrand as it expands into the rare disease space, with AI playing a major role in its marketing strategy.
Acadia CEO Catherine Owen Adams shares insights on the company's rebrand, rare disease expansion, and AI use in commercialization and marketing.
- Rebranding to expand into rare disease space
- Using AI in marketing strategy
- Challenges and benefits of marketing as a smaller biotech
Author's summary: Acadia Pharmaceuticals rebrands and expands into rare disease marketing with AI.